SUMMIT DETAILS
Science, Regulation and Public Health
Smoking is the biggest single cause of preventable death in the developed world with almost 1 billion users worldwide. The devastating effect of long-term smoking cannot be underestimated, with approximately half of all lifetime smokers dying from smoking related diseases and many more suffering a compromised quality of life. Despite decades of successful tobacco control efforts, we are still a long way from ending the smoking epidemic. The emergence of e-cigarettes has created one of the most controversial and contentious public health issues of a generation, with divisions appearing within longstanding professional alliances in both Tobacco Control and Public Health communities, despite a continued shared goal of protecting public health and ending the smoking epidemic.
The E-Cigarette Summit provides a neutral platform to explore the available peer reviewed evidence and debate the issues that are dividing scientists, health professionals and policy makers alike. So, are-cigarettes a valuable harm reduction strategy or a tacit U-turn on decades of effective tobacco control efforts? Whichever side of the debate you fall on, this is likely to be one of the most significant public health issues for a generation.
KEY TOPICS
The last 18 months have again seen momentous change in the US tobacco control and legal and regulatory landscape. The tragic EVALI outbreak, which in the minds of many still appears to have been related to nicotine-containing e-cigarettes triggered a wave of hostile government action and tobacco control activism directed at the e-cigarette industry. The EVALI crisis developed concurrently with the release of the 2019 NYTS data, which reflected another dramatic rise in past 30-day e-cigarette use by both high school and middle school youth. Both events appeared to play a role in the former president Trump September 2019 announcement of a decision to remove all flavored e-cigarette products from the marketplace. Though that announcement was partially moderated in FDA’s early 2020 guidance that directed the removal of flavored “cartridge based” products only, there is increased uncertainty around the future of flavored e-cigarettes in the U.S. Now, all U.S. e-cigarette products have been required to enter the premarket tobacco product application (PMTA) process with the FDA – a process that could lead to the removal from the market of a significant number of current products, while potentially answering critical questions regarding product safety and the role of flavors for those products that are able to successfully obtain a PMTA.
As we look ahead to the next 12 months, it remains to be seen how the long-awaited PMTA deadline will impact the potential of tobacco harm reduction (THR). Critical questions include whether FDA product review will provide a measure of stability of this brand new category and whether it will improve the tenor of the U.S. tobacco control conversation. This year’s E-Cigarette Summit USA comes on the eve of a historical transition for the US e-cigarette industry and under the shadow of the Covid pandemic – where socio economic health disparities have been bought in to sharp focus. As always, the Summit looks to provide an evidence based environment that encourages open and respectful dialogue on the key science and current public health topics, with a single aim of reducing smoking related death and disease.
SPEAKERS
Prof David L. Ashley Ph.D
RADM (retired) US Public Health Service: Research Professor
School of Public Health - Georgia State University
Prof Thomas J. Glynn, PhD
Adjunct Lecturer
Stanford Prevention Research Centre, Stanford University School of Medicine
Prof Robin Mermelstein
Distinguished Professor of Psychology and IHRP Director
University of Illinois, Chicago
Cliff Douglas, JD
Director, Tobacco Research Network, Adjunct Professor, Department of Health Management and Policy
School of Public Health, University of Michigan
Dr Vaughan W. Rees
Director of the Center for Global Tobacco Control
Harvard T.H. Chan School of Public Health
Prof Neal L. Benowitz MD
Professor of Medicine Emeritus (Active)
University of California, San Franciso
Andy Hyland
Scientific Principal Investigator, NIH/FDA PATH Study
Roswell Park Comprehensive Cancer Center
Prof Peter Hajek
Professor of Clinical Psychology & Director of the Tobacco Dependence Research Unit
Wolfson Institute of Public Health, Queen Mary University of London
Dr Jamie Hartmann-Boyce
Associate Professor and Editor, Cochrane Tobacco Addiction Group
Nuffield Department of Primary Care Health Sciences, University of Oxford
Prof Scott Sherman
Professor of Population Health, Medicine and Psychiatry
NYU Grossman School of Medicine
Associate Prof Jennifer Pearson
Associate Professor in Health Administration and Policy
School of Public Health, University of Nevada, Reno
Jeff Lynch
Facilitator Prevention/Intervention Education, CHOICES Prevention Programs
Tulare County Office of Education
Prof Kevin M. Gray, M.D
Professor of Psychiatry and Behavioral Sciences
Medical University of South Carolina
Dr Ray Niaura
Professor of Social & Behavioural Health & Co-Director of the Tobacco Research Lab
School of Global Public Health, New York University
Matthew R. Holman
Director, Office of Science (OS),Center for Tobacco Products (CTP)
U.S. Food and Drug Administration
Prof Kathleen. S Hoke, J.D.
Director of the Legal Resource Center for Public Health Policy
University of Maryland Carey School of Law
Prof Dorothy K. Hatsukami
Professor, Department of Psychiatry and Behavioral Sciences
University of Minnesota
Professor Ann McNeill
Professor of Tobacco Addiction
Institute of Psychiatry, Psychology & Neuroscience,, Kings College London
Dr. Nancy A. Rigotti, MD
Professor of Medicine, Harvard Medical School
Director, Tobacco Research & Treatment Center, Massachusetts General Hospital, Boston
If you cannot see the full list of speakers required for this page please make sure you have ordered all speakers in your custom list.
Edit Custom Order Here »
Only administrators can see this message
